Loading, please wait...
| DOWNLOAD SCHEDULE » | DOWNLOAD EVAL TEMPLATE » | CE INSTRUCTIONS » | REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Friday, November 22, 2019
St. Louis College of Pharmacy - Academic Research Building (ARB)
|
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
|
SESSION 1
1:00 – 1:45 pm
|
Alicia Yn, Pharm.D.
Axicabtagene ciloleucel versus Tisagenlecleucel for Relapsed/Refractory Diffuse Large B-cell Lymphoma
|
Kelsey Sachtleben, Pharm.D.
Evaluating the use of direct oral anticoagulants in thrombophilic disorders
|
Ashleigh Wallace, Pharm.D.
Aspirin for the Primary Prevention of ASCVD
|
Dan Ilges, Pharm.D.
Long-Acting Lipoglycopeptides for Osteomyelitis
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 2
1:55 – 2:40 pm
|
Cassandra Hacker, Pharm.D.
Use of Venetoclax in Treatment of Acute Myeloid Leukemia
|
Rachel Kiehne, Pharm.D.
The Use of Anticoagulation in Patients with Peripheral Artery Disease
|
Ara Gharabagi, Pharm.D.
Polycystic Kidney Disease: Updates in Therapeutics and Management
|
Kimberly Johnstone, Pharm.D.
Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORA) for the treatment of Opioid-Induced Constipation in pediatric patients
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 3
2:50 – 3:40 pm
|
John Talili, Pharm.D.
The use of Erythropoiesis-Stimulating Agents in the Setting of Cancer-Associated Anemia
|
Emily Frye, Pharm.D.
Reversal Strategies for Direct Oral Anticoagulants
|
Daniel Elliott, Pharm.D.
Pharmacologic Management for Postoperative Vasoplegic Syndrome
|
Jami Cain, Pharm.D.
Bravo for Spravato? A unique approach for treatment-resistant depression
|
Please join us for the third session of the 2019-2020 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third floor.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 2.25 contact hours. Participants must sign in AND complete an evaluation to receive credit.
Click here for a printable copy of the schedule
REGISTRATION & PARKING INFORMATION
This event has mutliple concurrent sessions. To register, click the green button below. You will be asked to log in. You will be registered for the whole day - please complete the evaluations for only those sessions that you attend. Unattended sessions will be removed from your account, based on sign-in records, within two weeks following Seminar.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 12:00 PM on Wednesday, November 13, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or by clicking here », to complete your parking request. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 12:00 PM on Wednesday, November 13, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or by clicking here », to complete your parking request. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website. Sessions you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block. To do so, participants must complete an online evaluation for those sessions attended no later than two weeks following the sessions. Participants must be logged on and registered in order to view and complete the evaluation(s). Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign in sheets, the offending participant forfeits CE credit.
Following successful completion of an evaluation, a report will be automatically submitted to CPE monitor using the date of birth and NABP e-Profile ID stored in your user profile. Please allow up to 48 hours for our systems to sync before credit becomes visible in your online NABP account. Participants are responsible for ensuring accuracy of credit reporting and receipt of credit in NABP. It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, St. Louis College of Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After two weeks, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close December 6, 2019 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify us in advance so that we may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Nov 22, 2019 01:00 AM - 04:00 AM
Fee
$0.00
CE Hours
9.00
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing high-dose salvage chemotherapy and autologous stem-cell transplantation have dismal survival outcomes with median overall survival of 6.2 months. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized patients with R/R DLBCL, demonstrating high remission rates and durable responses. Two CAR T-cell products – axicabtagene ciloleucel and tisagenlecleucel – have been FDA-approved for R/R DLBCL and a third may be FDA-approved in 2019. Despite similarities among these products, there are distinct differences in their design and studied patient population that can make direct comparison between them difficult. This seminar will attempt to describe the clinical outcomes behind their FDA approval, distinguish the differences between the current CAR T-cell products in R/R DLBCL, and the management of their primary toxicities.
Speaker(s)/Author(s)
|
Alicia Yn, Pharm.D. |
Activity Number
0033-0000-19-126-L01-P
Date:
11/22/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 304
Direct oral anticoagulants (DOACs) have proven to be safe and effective options for treatment and prevention of thrombotic events. Patients with inherited thrombophilic disorders such as protein C or S deficiency, factor V Leiden, antithrombin deficiency, or prothrombin G20210A mutation are a unique patient population at an increased risk for such thrombotic events. However, data supporting the use of DOACs in these populations is sparse. The objective of this presentation is to evaluate current literature and guideline recommendations pertaining to the role of DOACs in treatment and prevention of thrombotic events in patients with inherited thrombophilic disorders.
Speaker(s)/Author(s)
|
Kelsey Sachtleben, Pharm.D. |
Activity Number
0033-0000-19-127-L01-P
Date:
11/22/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305
Aspirin for the primary prevention of ASCVD is controversial. It has shown benefit in some populations, but not all. There has also been evidence of increased risk of bleeding in some populations. This presentation is aimed to help clinicians determine when aspirin for primary prevention could be beneficial in patients with ASCVD risk and when its use could be harmful.
Speaker(s)/Author(s)
|
Ashleigh Wallace, Pharm.D. |
Activity Number
0033-0000-19-128-L01-P
Date:
11/22/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 354
This program will discuss long-acting lipoglycopeptides in the context of osteomyelitis treatment, including their unique pharmacokinetic/pharmacodynamic properties, literature evaluation, and their place in therapy. The goal is for the audience gain confidence utilizing long-acting lipoglycopeptides to treat osteomyelitis utilizing the latest evidence, given the appropriate clinical situation.
Speaker(s)/Author(s)
|
Daniel Ilges, Pharm.D. |
Activity Number
0033-0000-19-125-L01-P
Date:
11/22/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 355
This presentation will briefly review AML epidemiology, goals of treatment, and guideline recommendations for induction therapy of patients age 60 and over. Evidence will be reviewed and analyzed for non-venetoclax and venetoclax-containing treatment options for induction therapy of older adults ineligible for intensive chemotherapy. A suggested treatment algorithm will be presented based on the evidence discussed. The goal of this presentation is to present the evidence behind the use of venetoclax in AML, and describe its place in therapy.
Speaker(s)/Author(s)
|
Cassandra Hacker, Pharm.D. |
Activity Number
0033-0000-19-124-L01-P
Date:
11/22/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304
Peripheral artery disease is associated with increased morbidity and mortality, including adverse cardiovascular events, limb ischemia, and amputation. Trials have shown that warfarin plus antiplatelet therapy is not superior to antiplatelet therapy alone. In October 2018, rivaroxaban received an FDA approval for reduction in the risk of major cardiovascular events in chronic PAD and CAD when used in combination with low-dose aspirin. This decision was based on results from the COMPASS trial. This presentation will examine the results of studies performed on the use of anticoagulation in patients with peripheral artery disease to prevent adverse cardiovascular outcomes. In addition, this seminar will address the external applicability of COMPASS.
Speaker(s)/Author(s)
|
Rachel Kiehne, Pharm.D. |
Activity Number
0033-0000-19-122-L01-P
Date:
11/22/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305
The disease state of PKD will be covered. The overall goal for this seminar is to properly educate clinicians on the management of ADPKD and ARPKD and their major complications so that they may feel more comfortable treating this patient population. Pathogenesis, treatment strategies, and the proper management of disease-associated complications using the most recent literature and guidelines will be discussed throughout the presentation. Questions and small case scenarios incorporating important concepts will be used as teaching materials interspersed during the seminar.
Speaker(s)/Author(s)
|
Ara Gharabagi, Pharm.D. |
Activity Number
0033-0000-19-130-L01-P
Date:
11/22/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354
This seminar will discuss the indications, safety, and efficacy of PAMORAs in adult and pediatric patients, as well as complications and side effects. The program will consist of a live lecture providing the audience with information on relevant literature relating to the expanding use of PAMORAS in oncology and critical care pediatric patients. The goal for the audience is to understand the mechanism of action of PAMORAs, their emerging role in therapy outside of adult oncology and palliative care patients, and to apply current adult practices to the pediatric setting.
Speaker(s)/Author(s)
|
Kimberly Johnstone, Pharm.D. |
Activity Number
0033-0000-19-123-L01-P
Date:
11/22/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355
Erythropoiesis-stimulating agents (ESAs) to manage anemia in cancer patients raises hemoglobin and reduces the use of RBCs. ESAs can be offered to patients with chemotherapy-associated anemia whose treatment is not curative in intent due to evidence of increased mortality and increased risk of cancer progression. ESAs also increase the risk of thromboembolic events. The goals for the audience are (1) Recognize the causes and presentation of cancer-associated anemia, (2) Discuss the pharmacology of erythropoiesis-stimulating agents, and (3) Distinguish the role of erythropoiesis-stimulating agents in cancer-associated anemia based on current guidelines and literature.
The overall structure of the CE activity will include background information on cancer associated anemia; background information, mechanism of action, and safety information of the ESAs; and discuss the current recommendations of the ASCO guidelines with a literature review component.
Speaker(s)/Author(s)
|
John Talili, Pharm.D. |
Activity Number
0033-0000-19-129-L01-P
Date:
11/22/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 304
Throughout the past few years there have been additional agents approved for the reversal of direct oral anticoagulants but the data behind the reversal agents is lacking. The currently FDA approved reversal agents include idarucizumab (Praxbind) and Andexanet alfa (Andexxa). Managing the reversal of direct oral anticoagulants has become a controversial topic over the past few years and there is limited data available to guide providers in the treatment choices. The goal for the audience is to identify the risk factors associated with bleeding, review available agents for reversing direct oral anticoagulants, and identify the currently recommended strategies for direct oral anticoagulation reversal.
Speaker(s)/Author(s)
|
Emily Frye, Pharm.D. |
Activity Number
0033-0000-19-121-L01-P
Date:
11/22/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 305
This presentation will provide an overview of the etiology, epidemiology, multi-factorial pathophysiology, and risk factors for post-operative vasoplegic syndrome. The disease state overview will be followed by a review of current vasopressor therapy utilized in the management of post-operative vasoplegic syndrome. This presentation will also review and analyze the available evidence for the utilization of corticosteroids, methylene blue, hydroxocobalamin, angiotensin II, and vitamin C/thiamine for post-operative vasoplegic syndrome.
The overall goal for the audience is to understand the disease state/risk factors and pharmacologic options for post-operative vasoplegic syndrome treatment.
The overall goal for the audience is to understand the disease state/risk factors and pharmacologic options for post-operative vasoplegic syndrome treatment.
Speaker(s)/Author(s)
|
Daniel Elliott, Pharm.D. |
Activity Number
0033-0000-19-120-L01-P
Date:
11/22/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 354
During the presentation, there will be a review of treatment-resistant depression as well as major depressive disorder. After reviewing these disease states we will cover the current treatment options and recommendations. Then, the conversation will move to discussing esketamine specifically and the trials that got this medication to the market and the efficacy and safety associated with the medication. The presentation will close with the presenter's recommendations for treatment and a suggested treatment algorithm. Assessment questions will be used throughout to follow with the learning objectives.
Speaker(s)/Author(s)
|
Jami Cain, Pharm.D. |
Activity Number
0033-0000-19-131-L01-P
Date:
11/22/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 355
